LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

Home・Stock List・MannKind Corp

MannKind Corp

Closed

SectorHealthcare

2.95 -1.34

Buy Sell

Overview

Share price change

24h

Current

Min

2.92

Max

Key metrics
By Trading Economics
Income	-671K -17M
Sales	-22M 90M
P/E Sector Avg	140.5 49.701
EPS	-0.02
Profit margin	-18.431
Employees	591
EBITDA	5.9M 3.4M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+152.17% upside

Dividends
By Dow Jones
Next Earnings	5 Aug 2026

Market Stats
By TradingEconomics
Market Cap	56M 924M
Previous open	4.29
Previous close	2.95

News Sentiment

By Acuity

34%

66%

93 / 345 Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

4.079 / 4.323 Support & Resistance

MannKind Corp Chart

Past performance is not a reliable indicator of future results.

Related News

19 May 2026, 20:36 UTC

Acquisitions, Mergers, Takeovers

Analog Devices to Buy Empower Semiconductor for $1.5 Billion

19 May 2026, 23:47 UTC

Market Talk

Nikkei May Decline as Concerns About Energy, Material Costs Persists -- Market Talk

19 May 2026, 23:34 UTC

Market Talk

Gold Edges Higher on Possible Technical Recovery -- Market Talk

19 May 2026, 23:28 UTC

Market Talk

Earnings

Global Forex and Fixed Income Roundup: Market Talk

19 May 2026, 23:28 UTC

Market Talk

Earnings

F&P Healthcare's Outlook Key for Investors -- Market Talk

19 May 2026, 23:10 UTC

Market Talk

Global Equities Roundup: Market Talk

19 May 2026, 23:10 UTC

Market Talk

Kiwi Property's Dividend Growth Reliant on Several Factors -- Market Talk

19 May 2026, 22:02 UTC

Earnings

ZTO Express (Cayman): Di Xu to Resign From Board

19 May 2026, 22:01 UTC

Earnings

ZTO Express (Cayman) 1Q Adj EPS 43c >ZTO

19 May 2026, 22:01 UTC

Earnings

ZTO Express (Cayman) 1Q EPS 39c >ZTO

19 May 2026, 22:00 UTC

Earnings

ZTO Express (Cayman) 1Q Rev $1.93B >ZTO

19 May 2026, 21:37 UTC

Earnings

Cracks Are Starting to Appear in the Chip Stock Rally -- Barrons.com

19 May 2026, 21:31 UTC

Acquisitions, Mergers, Takeovers

How NextEra Can Fix Dominion's Strange AI Problem -- Barrons.com

19 May 2026, 21:01 UTC

Earnings

Home Depot Beats Earnings Estimates as Shoppers Defy Inflation Fears. The Stock Advances. -- Barrons.com

19 May 2026, 20:58 UTC

Earnings

These Stocks Are Today's Movers: CoreWeave, Nvidia, Home Depot, Akamai, Agilysys, Micron, and More -- Barrons.com

19 May 2026, 20:46 UTC

Hot Stocks

Stocks to Watch Recap: ServiceNow, Home Depot, CoreWeave -- WSJ

19 May 2026, 20:43 UTC

Market Talk

Canada 30-Year Yield Hits Highest Level Since 2010 -- Market Talk

19 May 2026, 20:34 UTC

Earnings

James Hardie Industries Sees FY27 Sales $5.25B-$5.41B >JHX

19 May 2026, 20:32 UTC

Earnings

James Hardie Industries: Targeting Pro Forma Adjusted EBITDA Growth of 4% to 8% in FY27 >JHX

19 May 2026, 20:32 UTC

Earnings

James Hardie Industries 4Q EPS 5c >JHX

19 May 2026, 20:32 UTC

Earnings

James Hardie Industries 4Q Sales $1.4B >JHX

19 May 2026, 20:21 UTC

Acquisitions, Mergers, Takeovers

Analog Devices to Buy Empower Semiconductor for $1.5B

19 May 2026, 20:18 UTC

Market Talk

Canada CPI Data Has Accounting Quirk Related to Travel Tours -- Market Talk

19 May 2026, 20:13 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

19 May 2026, 20:13 UTC

Market Talk

'Hard to Square' Canada Rate Hikes Expectations Given Mild Core -- Market Talk

19 May 2026, 20:03 UTC

Acquisitions, Mergers, Takeovers

Analog Devices: Deal Further Advances Position as Strategic, System-Level Grid-To-Core Power Partner for Hyperscalers, AI Silicon Developers >ADI

19 May 2026, 20:03 UTC

Acquisitions, Mergers, Takeovers

Analog Devices: Phillips Will Continue Leading IVR Technology Efforts as Part of ADI >ADI

19 May 2026, 20:02 UTC

Acquisitions, Mergers, Takeovers

Analog Devices Will Acquire Empower in All-Cash Transaction for $1.5 B >ADI

19 May 2026, 20:02 UTC

Acquisitions, Mergers, Takeovers

Analog Devices to Acquire Empower Semiconductor, Expanding Its Next-Generation High-Density Power Portfolio for the AI Era

19 May 2026, 19:23 UTC

Market Talk

Oil Futures Slip With Market Back on U.S.-Iran Deal Watch -- Market Talk

Peer Comparison

Price change

MannKind Corp Forecast

Price Target

By TipRanks

152.17% upside

12 Months Forecast

Average 7.54 USD 152.17%

High 10 USD

Low 4.75 USD

Based on 8 Wall Street analysts offering 12 month price targets forMannKind Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Based on 8 analysts giving stock ratings to MannKind Corp - Dist in the past 3 months.

Technical Score

By Trading Central

4.079 / 4.323Support & Resistance

Bullish events outweigh bearish events.

All events are bearish.

Bearish events outweigh bullish events.

Sentiment

By Acuity

93 / 345 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.